Chronic Kidney Disease - Epidemiology Forecast Report (2019 to 2032) - Featuring Boehringer Ingelheim, GlaxoSmithKline, Keryx Biopharmaceuticals and Tricida - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chronic Kidney Disease - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

This "Chronic Kidney Disease - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Kidney Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Study Period: 2019-2032

Chronic Kidney Disease Understanding

The Chronic Kidney Disease epidemiology report gives a thorough understanding of Chronic Kidney Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chronic Kidney Disease in the US, Europe, and Japan. The report covers the detailed information of the Chronic Kidney Disease epidemiology scenario in seven major countries (US, EU5, and Japan).

Chronic Kidney Disease Epidemiology Perspective

The Chronic Kidney Disease epidemiology division provides insights into the historical and current patient pool and forecasted trend for every seven major countries. The Chronic Kidney Disease epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. The Chronic Kidney Disease epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chronic Kidney Disease Detailed Epidemiology Segmentation

The Chronic Kidney Disease epidemiology covered in the report provides historical as well as forecasted Chronic Kidney Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Chronic Kidney Disease report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Chronic Kidney Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chronic Kidney Disease Epidemiology Report and Model provide an overview of the global trends of Chronic Kidney Disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Chronic Kidney Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Kidney Disease
• The report provides the segmentation of the Chronic Kidney Disease epidemiology

Report Highlights

• 11-year Forecast of Chronic Kidney Disease epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Chronic Kidney Disease
• Cases of Chronic Kidney Disease by Mutation Types
• Chronic Kidney Disease Cases associated with Clinical Manifestations

KOL views

The publisher interviews, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Companies Mentioned

• Amgen
• Amag Pharmaceuticals
• Keryx Biopharmaceuticals
• Abbvie
• Vifor Pharma
• OPKO Health
• Chong Kun Dang Pharmaceutical
• GlaxoSmithKline
• Akebia Therapeutics
• FibroGen/Astellas Pharma/AstraZeneca
• Boehringer Ingelheim
• Tricida
• AstraZeneca
• Corvidia Therapeutics
• Reata Pharmaceuticals 

For more information about this report visit https://www.researchandmarkets.com/r/238fsl

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900